8-K - Bluejay Diagnostics, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Bluejay Diagnostics, Inc. furnished a response letter dated March 13, 2026, to NorthStrive Fund II LP regarding their March 11, 2026 letter suggesting acquisition of a Phase-1-ready therapeutic program for refractory chronic cough. The Company will evaluate the opportunity while focusing on Symphony platform advancement, SYMON II clinical study, manufacturing scale-up, and FDA submission to preserve cash and unlock shareholder value.

Key Takeaways

1Response letter sent to NorthStrive Fund II LP on March 13, 2026, by Neil Dey, President and CEO.

2NorthStrive suggested acquisition of Phase-1-ready therapeutic targeting refractory chronic cough.

3Company prioritizing Symphony platform, SYMON II study completion, manufacturing scale-up, and FDA submission.

4Board and management to review opportunity with advisors, acting in stockholders' best interests.

Current Report Details

Event Type

Regulation Fd

Exhibits Only

Disclosure

Voluntary

Variant

8-K

Items Reported

7.01

of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be “filed” for the purpose of the Securities Exchange Act of 1934,

Regulation Fd

9.01

. Financial Statements and Exhibits. (d) Exhibits 99.1 Letter to NorthStrive Fund II LP, dated March 13, 2026 104 Cover Page Interactive Data File (embedded wit

Exhibits Only

Source Document

Exhibits (2)

8-K

CURRENT REPORT

99.1

LETTER TO NORTHSTRIVE FUND II LP, DATED MARCH 13, 2026